Summit Therapeutics shares jumped on Thursday after trial results showed its experimental cancer drug performed better than Merck’s Keytruda. The outcome marks a major advance for Summit in lung cancer treatment. It could challenge Keytruda’s market dominance, which spans annual sales in the tens of billions of dollars.

Chipmaker Ambarella reported fiscal 2026 second-quarter earnings that slightly beat market expectations. The company’s fiscal third-quarter revenue guidance matched consensus forecasts. The update pushed AMBA shares higher.

Dovish remarks from Fed Governor Christopher Waller fueled a sharp rise across the crypto market on Thursday. Several bitcoin-linked instruments broke through key resistance levels. Risk appetite rebounded noticeably as investor concerns over the Fed’s policy path eased. The dovish signal added upside momentum to risk assets.

Ciena reported fiscal third-quarter results, with earnings coming in above market expectations. Revenue was slightly ahead of forecasts. The company also issued an October-quarter sales outlook that exceeded estimates. Despite the upbeat update, the stock declined.

Snowflake released its Q2 results, reporting revenue and profit that beat market expectations by a wide margin. The company also issued forward guidance that came in well above Wall Street estimates. Snowflake shares jumped following the release.

Hewlett Packard Enterprise reported third-quarter results that beat market expectations for both revenue and earnings, supported by strong expectations for growth in its AI infrastructure business. After the report, the stock traded unevenly rather than moving in a clear direction. The choppy reaction suggested investors were still divided as they digested the positive news.

Credo Technology reported fiscal first-quarter results and issued revenue guidance after the market close on Tuesday, both above market expectations. The stock still fell.

Novartis said its experimental multiple sclerosis therapy delivered successful results in two mid-stage studies. The update lifted the company’s shares sharply on Tuesday. The developments mark a key step forward as Novartis competes with rivals Roche and Sanofi.

Meta has reached a federal-level settlement in a multi-state lawsuit alleging social media addiction, agreeing to pay $18 billion. After the announcement, Meta’s stock moved unevenly. The case has drawn broader debate over teen mental health and platform accountability.